Notably, it has been found that BIRC5-induced specific T-cell reactivity is strongly correlated with tumor response and patient survival, suggesting that vaccination with BIRC5-derived peptides is a promising therapeutic strategy for melanoma24. This evidence concerns the gene BIRC5 and neoplasm.